云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀-B

休市中 07-05 16:08:07

19.400

+0.240

+1.25%

最高19.700	最低18.820	成交量164.89万
今开19.160	昨收19.160	日振幅4.59%
总市值63.08亿	流通市值63.08亿	总股本3.25亿
成交额3,179万	换手率0.51%	流通股本3.25亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀-B","latestPrice":19.4,"timestamp":1720166887015,"preClose":19.16,"halted":0,"volume":1648852,"delay":0,"floatShares":325164793,"shares":325164793,"eps":-2.887138,"marketStatus":"休市中","marketStatusCode":7,"change":0.24,"latestTime":"07-05 16:08:07","open":19.16,"high":19.7,"low":18.82,"amount":31789162,"amplitude":0.045929,"askPrice":19.4,"askSize":4000,"bidPrice":19.38,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-2.889895063990629,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720402200000},"adr":0,"listingDate":1602172800000,"adjPreClose":19.16,"openAndCloseTimeList":[[1720143000000,1720152000000],[1720155600000,1720166400000]],"volumeRatio":0.9436411931971778,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952/wiki","defaultTab":"wiki","newsList":[{"id":"2448441435","title":"云顶新耀-B07月04日主力资金流入138万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2448441435","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448441435?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:15","pubTimestamp":1720080921,"startTime":"0","endTime":"0","summary":"07月04日, 云顶新耀-B股价跌0.52%，报收19.16元，成交金额3111万元，换手率0.50%，振幅4.26%，量比1.00。云顶新耀-B今日主力资金净流入138万元，连续3日净流入，上一交易日主力净流入259万元，今日环比减少46.72%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为81.25%，平均涨幅为3.21%。该股近5个交易日下跌8.07%，主力资金累计净流入310万元；近20日主力资金累计净流入21万元，其中净流入天数为9日。该股主力净额占比0.02%，港股市场排名140/2644。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041615359573d40f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041615359573d40f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"2448900704","title":"云顶新耀-B(01952)下跌5.01%，报18.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448900704","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448900704?lang=zh_cn&edition=full","pubTime":"2024-07-02 14:24","pubTimestamp":1719901469,"startTime":"0","endTime":"0","summary":"7月2日，云顶新耀-B(01952)盘中下跌5.01%，截至14:24，报18.6元/股，成交4346.29万元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司，主要业务是在全球范围内引进专利许可，开发和商业化创新性疗法，以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来，公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物，以满足尚未满足的医疗需求，服务于大规模的潜在患者人群。截至2023年年报，云顶新耀-B营业总收入1.26亿元、净利润-8.44亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/02142441318451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1161","01952","BK1583"],"gpt_icon":0},{"id":"2448188397","title":"云顶新耀－Ｂ(01952)股价下跌5.005%，现价港币$18.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2448188397","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448188397?lang=zh_cn&edition=full","pubTime":"2024-07-02 14:24","pubTimestamp":1719901440,"startTime":"0","endTime":"0","summary":"[下跌股]云顶新耀－Ｂ(01952) 股价在下午02:24比前收市价下跌5.005%，现股价为港币$18.6。至目前为止，今日最高价为$19.72，而最低价为$18.6。总成交量为228.005万股，总成交金额为港币$4.346千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407021702/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2446277861","title":"创新药板块催化频出，港股创新药ETF(159567)跟踪指数走势较强，云顶新耀-B、来凯医药-B、翰森制药领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446277861","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446277861?lang=zh_cn&edition=full","pubTime":"2024-06-25 14:21","pubTimestamp":1719296513,"startTime":"0","endTime":"0","summary":"2024年6月25日，港股创新药板块走势占优。盘面上，云顶新耀-B领涨，来凯医药-B、翰森制药跟涨，港股创新药ETF市场热度较高，过去5个交易日日均成交额6447万元。受益于个股业绩超预期海内外新药研发数据优秀等利好催化，减重药、艾滋病预防用药、脑机接口等热点主题表现相对活跃。当前医药生物板块整体表现持续低迷，市场情绪有待恢复，建议以中长线视角布局高景气细分领域投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062514215595d55b32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062514215595d55b32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","02105","01952","BK1589","BK1161","03692","BK1574","BK1583","BK1191"],"gpt_icon":0},{"id":"2446865362","title":"云顶新耀-B午后涨超5% 长城证券给予买进的初始评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2446865362","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446865362?lang=zh_cn&edition=full","pubTime":"2024-06-25 13:14","pubTimestamp":1719292440,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　云顶新耀-B（01952）午盘上涨5.21%，现报21港元，成交额3257.03万港元。\n　　近日，长城证券给予云顶新耀买进的初始评级。 \n　　中金此前指，IgA肾病潜在市场空间较高，但产品收入的增长需要积极的商业化策略配合，建议关注耐赋康24年收入放量趋势。由于23年产品端销售略超预期，该行对24/25年销售收入持相对乐观态度。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-25/doc-inazxpen1562758.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-25/doc-inazxpen1562758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002939","01952"],"gpt_icon":0},{"id":"2446857456","title":"港股异动 | 云顶新耀-B(01952)涨超5% IgA肾病潜在市场空间较高 机构看好公司产品端销售收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2446857456","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446857456?lang=zh_cn&edition=full","pubTime":"2024-06-25 11:55","pubTimestamp":1719287734,"startTime":"0","endTime":"0","summary":"消息面上，云顶新耀日前宣布，公司在第22届亚太肾脏病学大会与韩国肾脏病学会第44届年会上展示耐赋康治疗优势及探索IgA肾病治疗新策略。此外，云顶新耀上月宣布，耐赋康在中国首张处方成功落地，标志着这款全球首个IgA肾病对因治疗药物开始正式惠及中国内地的患者。中金此前指，IgA肾病潜在市场空间较高，但产品收入的增长需要积极的商业化策略配合，建议关注耐赋康24年收入放量趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSTECH","01952","BK1161","HSCEI","BK1574","YANG","BK1583","07226"],"gpt_icon":0},{"id":"2446550038","title":"创新药有望加速进院，港股创新药ETF(159567)跟踪指数大幅上涨，复星医药、云顶新耀-B、翰森制药领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446550038","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446550038?lang=zh_cn&edition=full","pubTime":"2024-06-25 10:22","pubTimestamp":1719282126,"startTime":"0","endTime":"0","summary":"2024年6月25日，港股创新药板块走势占优。此举标志着广东省在深化医疗保障制度改革、优化药品供应保障体系方面迈出了新的一步。此措施有助于进一步规范药品市场，保障公众用药需求，提高药品可及性、促进创新药行业健康发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062510221095d4b7e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062510221095d4b7e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1593","03692","600196","BK1515","01952","02196","BK1583","BK1191","BK1589","BK1574","BK1161"],"gpt_icon":0},{"id":"2446856892","title":"云顶新耀-B(01952)上涨5.21%，报21.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446856892","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446856892?lang=zh_cn&edition=full","pubTime":"2024-06-25 10:20","pubTimestamp":1719282027,"startTime":"0","endTime":"0","summary":"6月25日，云顶新耀-B(01952)盘中上涨5.21%，截至10:20，报21.0元/股，成交1580.88万元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司，主要业务是在全球范围内引进专利许可，开发和商业化创新性疗法，以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来，公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物，以满足尚未满足的医疗需求，服务于大规模的潜在患者人群。截至2023年年报，云顶新耀-B营业总收入1.26亿元、净利润-8.44亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/25102041176995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1583","01952","BK1574"],"gpt_icon":0},{"id":"2446856747","title":"云顶新耀－Ｂ(01952)股价上升5.21%，现价港币$21.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2446856747","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446856747?lang=zh_cn&edition=full","pubTime":"2024-06-25 10:20","pubTimestamp":1719282000,"startTime":"0","endTime":"0","summary":"[上升股]云顶新耀－Ｂ(01952) 股价在上午10:20比前收市价上升5.21%，现股价为港币$21.0。至目前为止，今日最高价为$21.0，而最低价为$19.94。总成交量为75.6万股，总成交金额为港币$1.556千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2406251234/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1583","01952","BK1161"],"gpt_icon":0},{"id":"2444417326","title":"医药“科特估”推动估值重塑，港股创新药ETF(159567)跟踪指数大幅上涨，云顶新耀-B、中国生物制药、康诺亚-B领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2444417326","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444417326?lang=zh_cn&edition=full","pubTime":"2024-06-19 13:21","pubTimestamp":1718774502,"startTime":"0","endTime":"0","summary":"2024年6月19日，港股创新药板块走势占优。盘面上，云顶新耀-B领涨，中国生物制药、康诺亚-B跟涨，港股创新药ETF市场热度较高，近5日日均成交额达到7469万元。方正证券表示，从医药细分领域来看，创新药高端医疗器械、医疗新科技等新质生产力均属于知识技术密集型产业，行业空间大，但估值相对于美股仍有较大提升空间。创新药BD浪潮持续走高，产品出海驱动行业高速发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406191321469f4d6fc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406191321469f4d6fc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02162","BK1574","BK1587","BK1583","01177","BK1521","BK1191","BK1589","BK1515","BK1161","01952","09939"],"gpt_icon":0},{"id":"2441370407","title":"云顶新耀-B(01952)下跌5.18%，报21.05元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2441370407","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441370407?lang=zh_cn&edition=full","pubTime":"2024-06-06 10:16","pubTimestamp":1717640202,"startTime":"0","endTime":"0","summary":"6月6日，云顶新耀-B(01952)盘中下跌5.18%，截至10:16，报21.05元/股，成交3075.19万元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司，主要业务是在全球范围内引进专利许可，开发和商业化创新性疗法，以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来，公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物，以满足尚未满足的医疗需求，服务于大规模的潜在患者人群。截至2023年年报，云顶新耀-B营业总收入1.26亿元、净利润-8.44亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/06101640923077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01952","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"2441730988","title":"云顶新耀－Ｂ(01952)股价下跌5.18%，现价港币$21.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2441730988","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441730988?lang=zh_cn&edition=full","pubTime":"2024-06-06 10:15","pubTimestamp":1717640100,"startTime":"0","endTime":"0","summary":"[下跌股]云顶新耀－Ｂ(01952) 股价在上午10:15比前收市价下跌5.18%，现股价为港币$21.05。至目前为止，今日最高价为$22.55，而最低价为$21.05。总成交量为134.6万股，总成交金额为港币$2.913千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD240606673/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01952","BK1574","BK1583"],"gpt_icon":0},{"id":"2439695195","title":"云顶新耀-B05月31日主力资金流入244万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2439695195","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439695195?lang=zh_cn&edition=full","pubTime":"2024-05-31 16:16","pubTimestamp":1717143394,"startTime":"0","endTime":"0","summary":"05月31日, 云顶新耀-B股价涨1.15%，报收22.05元，成交金额6961万元，换手率0.96%，振幅5.96%，量比0.93。云顶新耀-B今日主力资金净流入244万元，连续3日净流入，上一交易日主力净流入85万元，今日环比增加187.06%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为86.67%，平均涨幅为3.21%。该股近5个交易日下跌4.56%，主力资金累计净流出240万元；近20日主力资金累计净流入1528万元，其中净流入天数为11日。该股主力净额占比0.03%，港股市场排名150/2628。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405311617199f09ad27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405311617199f09ad27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1583","01952"],"gpt_icon":0},{"id":"2439847299","title":"云顶新耀-B(01952)上涨5.28%，报22.95元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2439847299","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439847299?lang=zh_cn&edition=full","pubTime":"2024-05-31 09:34","pubTimestamp":1717119251,"startTime":"0","endTime":"0","summary":"5月31日，云顶新耀-B(01952)盘中上涨5.28%，截至09:34，报22.95元/股，成交1920.34万元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司，主要业务是在全球范围内引进专利许可，开发和商业化创新性疗法，以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来，公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物，以满足尚未满足的医疗需求，服务于大规模的潜在患者人群。截至2023年年报，云顶新耀-B营业总收入1.26亿元、净利润-8.44亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/31093440843024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01952","BK1574","BK1583"],"gpt_icon":0},{"id":"2439552069","title":"云顶新耀-B(01952)上涨5.29%，报23.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2439552069","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439552069?lang=zh_cn&edition=full","pubTime":"2024-05-29 09:30","pubTimestamp":1716946226,"startTime":"0","endTime":"0","summary":"5月29日，云顶新耀-B(01952)盘中上涨5.29%，截至09:30，报23.9元/股，成交686.38万元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司，主要业务是在全球范围内引进专利许可，开发和商业化创新性疗法，以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来，公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物，以满足尚未满足的医疗需求，服务于大规模的潜在患者人群。截至2023年年报，云顶新耀-B营业总收入1.26亿元、净利润-8.44亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/29093040810586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1161","01952","BK1583"],"gpt_icon":0},{"id":"2439555354","title":"云顶新耀(01952)合作伙伴Calliditas(CALT.US)拟接受旭化成集团约11亿美元要约收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2439555354","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439555354?lang=zh_cn&edition=full","pubTime":"2024-05-29 07:59","pubTimestamp":1716940795,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀合作伙伴Calliditas Therapeutics AB宣布，旭化成集团提出以111.64亿瑞典克朗的价格收购Calliditas，作为其在医疗保健领域国际扩张计划的一部分。此要约收购比Calliditas于5月27日收盘价溢价约83%。2019年6月，云顶新耀与Calliditas签订独家授权许可协议，获得在大中华地区和新加坡开发以及商业化耐赋康的权利。要约收购完成后，云顶新耀也将与Calliditas及旭化成集团紧密合作，顺利完成衔接工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1127424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","01952","BK4007","CALT","BK1161","BK1574"],"gpt_icon":0},{"id":"2438345869","title":"【券商聚焦】长城证券首予云顶新耀(01952)“买入”评级 指依拉环素、耐赋康将稳定贡献业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2438345869","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438345869?lang=zh_cn&edition=full","pubTime":"2024-05-28 15:38","pubTimestamp":1716881884,"startTime":"0","endTime":"0","summary":"2023年依拉环素、耐赋康成功上市，分别贡献收入9900万、2100万元。该行指，耐赋康是全球首款获批的专治IgA肾病创新药。泽托佐米全球临床II期试验结果积极，同时表现出良好的安全性和耐受性。该行表示，2024年依拉环素、耐赋康将稳定贡献业绩，伊曲莫德澳门地区获批上市、头孢吡肟-他尼硼巴坦将进入NDA阶段，中短期内有望成为新增长点。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/YjI3NDA0ZDhiMGQ3ZDhlYjY1NzQ2OTEyNjkyMTk4MTc4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YjI3NDA0ZDhiMGQ3ZDhlYjY1NzQ2OTEyNjkyMTk4MTc4.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1937672","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","002939"],"gpt_icon":0},{"id":"2438841834","title":"南向资金5月24日净买入云顶新耀-B101.90万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2438841834","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438841834?lang=zh_cn&edition=full","pubTime":"2024-05-27 09:31","pubTimestamp":1716773485,"startTime":"0","endTime":"0","summary":"5月24日, 南向资金增持云顶新耀-B101.90万股，连续3日增持。截止当日收盘，港股通共持有云顶新耀-B12030.75万股，占流通股37.04%。云顶新耀-B近5个交易日下跌1.28%，港股通累计增持215.45万股；近20个交易日下跌1.91%，港股通累计增持383.35万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405270942069ef00d2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405270942069ef00d2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2437726182","title":"云顶新耀-B(01952)下跌5.15%，报22.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2437726182","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437726182?lang=zh_cn&edition=full","pubTime":"2024-05-24 09:57","pubTimestamp":1716515853,"startTime":"0","endTime":"0","summary":"5月24日，云顶新耀-B(01952)盘中下跌5.15%，截至09:57，报22.1元/股，成交2615.13万元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司，主要业务是在全球范围内引进专利许可，开发和商业化创新性疗法，以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来，公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物，以满足尚未满足的医疗需求，服务于大规模的潜在患者人群。截至2023年年报，云顶新耀-B营业总收入1.26亿元、净利润-8.44亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/24095740763411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1583","01952","BK1574"],"gpt_icon":0},{"id":"2437253594","title":"云顶新耀-B05月22日主力资金流入109万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2437253594","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437253594?lang=zh_cn&edition=full","pubTime":"2024-05-22 16:16","pubTimestamp":1716365780,"startTime":"0","endTime":"0","summary":"05月22日, 云顶新耀-B股价涨3.71%，报收23.75元，成交金额1.04亿元，换手率1.36%，振幅7.86%，量比0.96。云顶新耀-B今日主力资金净流入109万元，连续3日净流入，上一交易日主力净流入211万元，今日环比减少48.34%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为93.33%，平均涨幅为3.39%。该股近5个交易日下跌6.45%，主力资金累计净流出425万元；近20日主力资金累计净流入3927万元，其中净流入天数为12日。该股主力净额占比0.01%，港股市场排名240/2623。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405221617148b236528&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405221617148b236528&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","BK1583","01952"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":-0.1261},{"period":"3month","weight":-0.1121},{"period":"6month","weight":0.0232},{"period":"1year","weight":-0.0513},{"period":"ytd","weight":-0.0718}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":-0.0339},{"period":"3month","weight":0.0643},{"period":"6month","weight":0.0765},{"period":"1year","weight":-0.0396},{"period":"ytd","weight":0.0441}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事疗法的特许、临床开发及商业化业务，以解决尚未满足的医疗需求。该公司一直专注于创新候选药物的研发。该公司已开发极具前景的临床阶段候选药物产品组合，覆盖肿瘤、免疫学、心肾疾病及感染性疾病。该公司主要在大中华及亚太区其他新兴市场提供产品与服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.043978},{"month":2,"riseRate":0.25,"avgChangeRate":0.025861},{"month":3,"riseRate":0.25,"avgChangeRate":-0.030941},{"month":4,"riseRate":0.25,"avgChangeRate":-0.098869},{"month":5,"riseRate":0.5,"avgChangeRate":-0.010924},{"month":6,"riseRate":0.75,"avgChangeRate":0.281644},{"month":7,"riseRate":0,"avgChangeRate":-0.152328},{"month":8,"riseRate":0,"avgChangeRate":-0.206077},{"month":9,"riseRate":0.666667,"avgChangeRate":0.011102},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.050127},{"month":11,"riseRate":0.5,"avgChangeRate":0.116383},{"month":12,"riseRate":0.75,"avgChangeRate":0.148847}],"exchange":"SEHK","name":"云顶新耀-B","nameEN":"EVEREST MED - B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀-B,01952,云顶新耀-B股票,云顶新耀-B股票老虎,云顶新耀-B股票老虎国际,云顶新耀-B行情,云顶新耀-B股票行情,云顶新耀-B股价,云顶新耀-B股市,云顶新耀-B股票价格,云顶新耀-B股票交易,云顶新耀-B股票购买,云顶新耀-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}